1 Result(s)

Article

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson’s disease (PD) and LRRK2 kinase inhibitors are currently being tested in early phase clinical trials. In or...

C. P. Gonzalez-Hunt, E. A. Thacker, C. M. Toste, S. Boularand… in Scientific Reports (2020)